Oncology-focused healthcare company  (NASDAQ: NVCR) wasn't much of a cure for anyone's ill finances on Thursday. Its share price dived by nearly 8% on the day after management released its latest set of quarterly results. That decline was notably steeper than the 1.2% dip of the benchmark S 500 index.

For its third quarter, Novocure collected total revenue of slightly over $127 million. That represented a year-over-year decline of 3%, and missed the consensus analyst estimate of almost $129 million.

As for the bottom line, the healthcare company's net loss amounted to $49.5 million, or $0.46 per share. While this bettered the average prognosticator forecast of a $0.53-per-share loss, it was nearly double the $26.6 million shortfall in the same quarter of 2022.

Continue reading

Source Fool.com